A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer

被引：18

作者：

Iwase, H. ^{[1
]}

Shimada, M. ^{[1
]}

Tsuzuki, T. ^{[1
]}

Ina, K. ^{[2
]}

Sugihara, M. ^{[3
]}

Haruta, J. ^{[4
]}

Shinoda, M. ^{[5
]}

Kumada, T. ^{[6
]}

Goto, H. ^{[7
]}

机构：

[1] Nagoya Med Ctr, Nagoya, Aichi, Japan

[2] Nagoya Mem Hosp, Nagoya, Aichi, Japan

[3] Meitetsu Hosp, Nagoya, Aichi, Japan

[4] Japan Red Cross Nagoya First Hosp, Nagoya, Aichi, Japan

[5] Toyota Mem Hosp, Toyota, Japan

[6] Ogaki Municipal Hosp, Ogaki, Japan

[7] Nagoya Univ, Sch Med, Nagoya, Aichi 466, Japan

来源：

ONCOLOGY | 2011年 / 80卷 / 1-2期

关键词：

Gastric cancer; Combination therapy; Paclitaxel; S-1; Cisplatin; Phase II; CLINICAL-ONCOLOGY-GROUP; PLUS CISPLATIN; 5-FLUOROURACIL; COMBINATION; TRIAL; INFUSION; FLUOROURACIL; CHEMOTHERAPY; METHOTREXATE; DOXORUBICIN;

D O I：

10.1159/000328746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: To carry out a phase II multi-center study on the efficacy and safety of triple combination therapy with paclitaxel, S-1, and cisplatin in patients with unresectable/ metastatic gastric cancer. Methods: A total of 63 patients from 8 institutions were included in this study. Paclitaxel (160 mg/m(2)) was administered by infusion for 3 h on the first day. S-1 (70 mg/m(2)/day) was administered orally for 14 consecutive days from the first day. Cisplatin (60 mg/m(2)) was administered intravenously over 24 h on day 14 of every 28-day cycle. Results: All 63 patients were assessed for clinical efficacy and safety. A total of 259 cycles of treatment were administered (median 4, range 1-10). Grade 3-4 toxicities included neutropenia in 30.2%, thrombocytopenia in 12.7%, and anemia in 11.1%. There was no grade 3-4 non-hematological toxicity or treatment-related death. Complete response was observed in 6 patients and partial response in 34 patients. The overall response rate was 63.5%. The median progression-free survival and response duration were 8.0 and 8.8 months, respectively, and median survival time was 15 months. Conclusions: Triple combination therapy with paclitaxel, S-1, and cisplatin showed promising safety and efficacy profiles with the potential to become a standard regimen for unresectable/metastatic gastric cancer. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：76 / 83

页数：8

共 37 条

[21] Global cancer statistics, 2002 [J].